Abstract
Two patients with disseminated mantle-cell lymphoma relapsed 24 and 13 months, respectively, after high-dose chemotherapy and autologous stem cell transplantation (autoSCT). Both patients had an HLA-identical sibling and received an allogeneic stem cell transplant (alloSCT) 32 and 18 months after autologous transplant, after conditioning with fractionated 12 Gy total body irradiation plus cyclophosphamide 120 mg/kg. They are both alive and in complete remission 24 months after transplant. Both patients have developed chronic graft-versus-host disease and their Karnofsky performance status is 90%. AlloSCT may offer a useful approach in a subgroup of patients with mantle-cell lymphoma who have relapsed after autologous transplantation. Bone Marrow Transplantation (2000) 26, 677–679.
Similar content being viewed by others
References
Banks PM, Chan J, Clearly ML et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic, and molecular data Am J Surg Pathol 1992 16: 637–640
Bosch F, Jares P, Campo E et al. PRAD1/Cyclin D1 gene overexpression in chronic lymphoprolypherative disorders: a highly specific marker of mantle cell lymphoma Blood 1994 84: 2726–2732
Bosch F, López-Guillermo A, Campo E et al. Mantle cell lymphoma. Presenting features, response to therapy, and prognostic factors Cancer 1998 82: 567–575
Shivdasani RA, Hess JL, Skarin AT et al. Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma J Clin Oncol 1993 11: 802–811
Steward D, Vose J, Weisenburger D et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma Ann Oncol 1995 6: 263–266
Khouri I, Romaguera J, Kartajian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma J Clin Oncol 1998 16: 3803–3809
Freedman AS, Neuberg D, Gribben JG et al. High-dose chemo-radiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission J Clin Oncol 1998 16: 13–18
Tsai T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation Bone Marrow Transplant 1997 20: 859–863
de Lima M, van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma Bone Marrow Transplant 1997 19: 121–127
Fisher R, Dahlberg S, Nathwani B et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including mucosal-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study Blood 1995 85: 1075–1082
Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87–2 J Clin Oncol 1997 15: 1131–1137
Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540–1545
Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma Blood 1997 90: 4201–4205
van Biesen KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Bone Marrow Transplant 1997 19: 977–982
Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 1991 77: 649–653
Adkins D, Brown R, Goodnough LT et al. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation Bone Marrow Transplant 1998 21: 97–99
Corradini P, Ladetto M, Astolfi M et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma Br J Haematol 1996 94: 376–378
Milpied N, Gaillard F, Moreau P et al. High-dose therapy with stem cell transplantation for mantle-cell lymphoma: results and prognostic factors, a single center experience Bone Marrow Transplant 1998 22: 645–650
Barret AJ, Locatelli F, Treleaven JG et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favorable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party Br J Haematol 1991 79: 567–574
Acknowledgements
This work has been supported in part by grants SGR 1998/00111 from the Comissionat per a Universitats i Recerca (Generalitat Catalunya), and FISS-98/995 and 98/0380 from the Fondo de Investigaciones Sanitarias de la Seguridad Social, Spanish Ministry of Health. We wish to thank Anna Bauer for the English grammar review of the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martínez, C., Carreras, E., Rovira, M. et al. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 26, 677–679 (2000). https://doi.org/10.1038/sj.bmt.1702567
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702567
- Springer Nature Limited
Keywords
This article is cited by
-
Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)
Annals of Hematology (2014)
-
Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?
Bone Marrow Transplantation (2009)
-
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma
Bone Marrow Transplantation (2008)
-
Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma
Bone Marrow Transplantation (2003)
-
Mantle cell lymphoma: Therapeutic strategies are different from CLL
Current Treatment Options in Oncology (2003)